Salute e Benessere

Galapagos Creates New Subscription Right Plan

Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created,...
Nasdaq GlobeNewswire
27/05/2025

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs…

Jefferies Global Healthcare ConferenceChris Fox, EVP U.S. Commercial and Dr. Eric Hughes, EVP Global R&D and Chief Medical Officer Wednesday, June 4, 2025, at 9:20 am ET Goldman Sachs 46 thAnnual Global Healthcare ConferenceRichard Francis, President & CEO Tuesday, June 10, 2025, at 8:00 am ET To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the...
Nasdaq GlobeNewswire
27/05/2025

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCopenhagen, Denmark, May 27, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares…
Nasdaq GlobeNewswire
27/05/2025

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference…

Daix (France), New York City (New York, United States), May 27, 2025– Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a...
Nasdaq GlobeNewswire
27/05/2025

CARBIOS signs its first biorecycled PET sales contracts with two global…

CARBIOS has signed two multi-year commercial contracts for biorecycled PET from its Longlaville plant, with L'ORÉAL and L'Occitane en Provence, and has moved forward with the execution of this future plant's strategyThese initial commercial contracts confirm market demand for high-quality, recycled and recyclable PET from enzymatic recyclingClermont-Ferrand (France), 27 May 2025 (17.45 CEST).CARBIOS(Euronext Growth Paris: ALCRB), a pioneer in the development and...
Nasdaq GlobeNewswire
27/05/2025

Wound Care Market Value worth $29.57 billion by 2030 - Exclusive Report by The…

For More Information and To Stay Updated on The Latest Developments in The Global Wound Care Market Share, Download the Sample Pages: https://www.theresearchinsights.com/request_sample?id=427 For More Information and To Stay Updated on The Latest Developments in The Global Wound Care Market Share, Download the Sample Pages:https://www.theresearchinsights.com/request_sample?id=427 Market Overview and Growth Trajectory: Wound Care Market Growth: According to an...
PR Newswire
27/05/2025

Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035…

For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 Key Market Drivers and Trends The RWE oncology solutions market is witnessing strong growth, primarily driven by the shift towards patient-centric healthcare models and the adoption of cloud-based RWE platforms that...
PR Newswire
27/05/2025

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global…

Media ReleaseCOPENHAGEN, Denmark; May 27, 2025 Genmab A/S (Nasdaq:GMAB)announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the 46 th Goldman Sachs Annual Global Healthcare Conferencein Miami, Floridaat 8:00AMEDT (2:00 PM CEST)on June 9 , 2025 . A webcast of the fireside chat will be available on Genmab's website at...
Nasdaq GlobeNewswire
27/05/2025

Forte Medical Revolutionises Women's Routine Health with Peezy Midstream

Innovative Device Brings UTI and Antenatal Screening into the 21st Century with Unmatched Dignity, Hygiene and Accuracy Peezy Midstream. This pioneering device transforms routineurinary tract infection (UTI)andantenatal urine screeningsfor millions of women, by capturing urine specimens that are fit for purpose and guideline compliant.Invented by NHS GP,Dr Vincent Fortein response to the inaccurate, unhygienic nature of traditional urine collection methods. Peezy Midstream...
Nasdaq GlobeNewswire
27/05/2025

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody…

BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed using Biolojic's Multibody Platform, which generates Antibodies capable of addressing multiple disease targets Collaboration builds on Teva's Pivot to Growth strategy to step up innovation in Teva's innovative pipelineREHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May27, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd., (NYSE and...
Nasdaq GlobeNewswire
27/05/2025

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to…

Atif Abbas, M.D. joins as Chief Medical Officer Atif Abbas, M.D. joins as Chief Medical Officer CAMBRIDGE, England , May 27, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced dosing of its first patient in a collaboration with Coherus BioSciences, Inc., commencing a Phase1b /2 study evaluating STC-15, its first-in-class lead program, in combination with...
PR Newswire
27/05/2025

GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to…

Under terms of the collaboration, GRIN is to receive $50 million upfront, and is eligible to receive up to $520 million in milestones and tiered royalties in addition to shared development costs Under terms of the collaboration, GRIN is to receive$50 millionupfront, and is eligible to receive up to$520 millionin milestones and tiered royalties in addition to shared development costs GRIN will continue to lead global development and retains exclusive rights for radiprodil inthe...
PR Newswire
27/05/2025

BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025…

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, to be held in Chicago, IL, from May 30 to June 3, 2025. The data highlight continued progress of the Company's clinical programs consisting of complementary therapeutic modalities, including mRNA cancer immunotherapies,...
Nasdaq GlobeNewswire
27/05/2025

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma…

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicagoon Saturday, May 31 st, 2025 –- Theriva senior management to attend the ASCO conference and participate in an off-site investigator meeting to review the topline data from the VIRAGE Phase 2b clinical trial of VCN-01 in first-line metastatic...
Nasdaq GlobeNewswire
27/05/2025

IM Cannabis Provides Corporate Updates

Meeting Results Meeting Results Further to its press releases dated Aprill 11, 2025 (the "April 11Release ") andMay 7, 2025(the "May 7Release "), the Company is pleased to announce results of its annual general and special meeting, held onFriday, May 23, 2025(the " Meeting "). Capitalized terms not otherwise defined in this section have the meanings attributed to them in theApril 11Release. At the Meeting, there were 60 shareholders represented in person or by...
PR Newswire
27/05/2025

Junshi Biosciences Announces Ongericimab's sNDA Approval in China

® )) for: 1) adult patients with heterozygous familial hypercholesterolemia (“HeFH”); 2) alone or in combination with ezetimibe, in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated. Ongericimab has become China's first domestic PCSK9-targeted drug approved for statin-intolerant patients.According to the Chinese Guidelines for Lipid Management (2023), cardiovascular disease is the leading cause of death among...
Nasdaq GlobeNewswire
27/05/2025

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Basel, May 27, 2025- Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one...
Nasdaq GlobeNewswire
27/05/2025

Disclosure of Shareholding – Gjelsten Holding AS

Issuer:Zelluna ASAISIN:NO0013524942Date of event triggering the notification:27 May 2025Threshold crossed:5%In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten Holding AS ("Gjelsten") hereby notifies that its ownership interest in Zelluna ASA ("Zelluna") has fallen below the 5% threshold. Following a share capital increase in Zelluna through a private placement registered in VPS on 27 May 2025, Gjelsten's ownership has changed as follows:Previous...
Nasdaq GlobeNewswire
27/05/2025

ZLNA – New registered share capital

The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises, and the Company's new registered share capital is NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1.For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASAEmail:hans.eid@zelluna.comPhone: +47 482 48632About Zelluna ASAZelluna's mission is to deliver transformative treatments with the...
Nasdaq GlobeNewswire
27/05/2025

Evaxion announces business update and first quarter 2025 financial results

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results. Business highlights (since last quarterly update)Evaxion has made good progress with continued execution of our strategy and plans. We have achieved the first two milestones for the year and are tracking towards future milestones and value catalysts. Highlights include: Continued...
Nasdaq GlobeNewswire
27/05/2025

Biogen and City Therapeutics Announce Strategic Research Collaboration to…

Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology from Biogen. The collaboration will initially focus on a single target that mediates key central nervous system diseases, utilizing tissue enhanced delivery...
Nasdaq GlobeNewswire
27/05/2025

SciBase reaches milestone with over 300,000 patients tested with Nevisense

About Nevisense About Nevisense Designed to augment the capabilities of traditional dermoscopy,Nevisenseleverages the unique electrical properties of skin tissue to provide clinicians with objective data to support their clinical assessment. The device deliverspersonalized resultsthat help guide risk-aligned management strategies for patients with potentially malignant skin lesions. Withover 60 peer-reviewed clinical publicationsand studies, Nevisense has been shown to...
PR Newswire
27/05/2025

See All AI Raises $33 Million to Bring Revolutionary AI-Based Sliceable…

Groundbreaking platform generates high-resolution 3D models with 1mm cross-sectional slices from as few as two intraoperative fluoroscopic X-ray images, eliminates the need for pre-operative scans, and delivers precise intraoperative device tracking using visible light. Recently completed a second milestone product demonstration for the surgical and investor communities, with notices of allowable subject matter in three foundational U.S. patents. In its second successful product...
Nasdaq GlobeNewswire
27/05/2025

Strüngmann Award Committee Announces 2025 Finalists Recognizing Outstanding Life…

The selected finalists have demonstrated entrepreneurial execution and translational potential for a range of scientific approaches The winner(s) will be officially announced on July 3, 2025, and will receive an EUR 100,000 cash prize Munich, Germany, May 27, 2025– TheStrüngmann Awardselection committee today announced this year's award finalists. The three companies and their founders highlight the exceptional and internationally successful leaders emerging from the DACH...
Nasdaq GlobeNewswire
27/05/2025
Altri  Comunicati